- $177.44m
- $62.41m
- $6.39m
U.S. STOCKS ON THE MOVE-Novavax, Tiziana, Hempacco
Frequency Therapeutics up on completing enrollment in hearing loss therapy trial
Brief: Frequency Therapeutics Completes Enrollment Of Phase 2B Study Of FX-322 For The Treatment Of Sensorineural Hearing Loss
Frequency Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Frequency Therapeutics Inc expected to post a loss of 67 cents a share - Earnings Preview
Brief: Frequency Therapeutics Inc - Qtrly Loss Per Share $0.67
Brief: Frequency Therapeutics Inc - On April 8, Co Announced Reduction In Force Of Approximately 30% Of Its Workforce
Brief: Frequency Therapeutics Says On Mar 25, Peter Pfreundschuh Notified Co He Was Stepping Down As CFO Of The Company
Brief: Frequency Therapeutics Provides Business Updates, Reports Fourth Quarter
Brief: Frequency Therapeutics Entered Into Equity Distribution Agreement With Oppenheimer & Co Inc
Brief: Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise
Frequency Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Frequency Therapeutics Q3 Net Loss Per Share $0.73
Frequency Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview
Brief: Frequency Therapeutics Reports Unaudited Cash, Cash Equivalents, Marketable Securities $160.5 Million
Brief: Frequency Therapeutics Announces First Subject Dosed In FX-322 Phase 2B Acquired Sensorineural Hearing Loss (Snhl) Study
Brief: Frequency Therapeutics Inc Announces New FX-322 Results
Frequency Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Frequency Therapeutics - Expects Existing Cash, Cash Equivalents, Marketable Securities To Be Sufficient To Fund Operations Into 2023